Reply to M. Mo et al

Affiliations

¹ Manish A. Shah, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Luis A. Herráaez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Amit Garg, Genentech, South San Francisco, CA; and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

Comment

Manish A Shah et al. J Clin Oncol. 2018.

. 2018 Jan 20;36(3):303.

doi: 10.1200/JCO.2017.75.2758. Epub 2017 Nov 21.

¹ Manish A. Shah, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Luis A. Herráaez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Amit Garg, Genentech, South San Francisco, CA; and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

No abstract available

Comment on

HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
Shah MA, Xu RH, Bang YJ, Hoff PM, Liu T, Herráez-Baranda LA, Xia F, Garg A, Shing M, Tabernero J. Shah MA, et al. J Clin Oncol. 2017 Aug 1;35(22):2558-2567. doi: 10.1200/JCO.2016.71.6852. Epub 2017 Jun 2. J Clin Oncol. 2017. PMID: 28574779 Clinical Trial.
The HELOISE Study: Concerns About Trial Design.
Mo M, Li Y, Zhu J. Mo M, et al. J Clin Oncol. 2018 Jan 20;36(3):302. doi: 10.1200/JCO.2017.75.2139. Epub 2017 Nov 21. J Clin Oncol. 2018. PMID: 29161202 No abstract available.